【レポートの概要(一部)】
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview
Orphan medicines legislation
Orphan medicines centralized procedure in US/EU
Product registration process for orphan drugs in Japan
Orphan drug designations and approvals
Annual cost of orphan drugs
R&D costs for orphan and non-orphan drugs
PART 06: Pipeline snapshot
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by product
Global biologic orphan drugs market
Global non-biologic orphan drugs market
PART 09: Geographical segmentation
Orphan drugs market in Americas
Orphan drugs market in EMEA
Orphan drugs market in APAC
PART 10: Market drivers
Shorter development timelines
Assistance from regulatory bodies
Incentives for developing orphan drugs
High return on investment
Exemption from pricing constraints
PART 11: Impact of drivers
PART 12: Market challenges
High cost of drug development
Decreased investment in marketing
Complications in conducting clinical trials
Unknown pathophysiology
Adverse policies of FDA
PART 13: Impact of drivers and challenges
PART 14: Market trends
Increased focus on biological drugs
Growing awareness of orphan drugs
Channel marketing strategy
Expansion of business
Entry into untapped market
PART 15: Vendor landscape
Competitive scenario
Major vendors 2014
Worldwide orphan drug sales revenue: Top 17 companies 2013
Top 10 orphan drugs in US 2014
Other prominent vendors
PART 16: Key vendor analysis
BMS
Celgene
Novartis
Pfizer
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: History of orphan medicines legislation
Exhibit 03: Incentives provided by US regulation
Exhibit 04: Incentives provided by Japanese regulation
Exhibit 05: Incentives provided by EU regulation
Exhibit 06: Incentives provided by Australian regulation
Exhibit 07: Incentives provided by South Korean regulation
Exhibit 08: Incentives provided by Singapore regulation
Exhibit 09: Orphan drug regulatory process in EU/US
Exhibit 10: Orphan drug registration process in Japan
Exhibit 11: Orphan drug development and regulatory challenges
Exhibit 12: Orphan drug designations and approvals in US 2000-2014
Exhibit 13: Number of novel orphan molecular entities launched in US 2004-2013
Exhibit 14: Novel orphan molecular entities launched in US 2013
Exhibit 15: Number of orphan drug designations and approvals in Japan 2000-2012
Exhibit 16: Number of orphan medicinal products launched in Europe 2002-2014
Exhibit 17: Top orphan drug designation indications in EU 2014
Exhibit 18: Approved and designated orphan pharmaceutical products in US, EU, Japan, and Australia
Exhibit 19: Cumulative orphan designations in US, EU, and Japan per year 2000-2013
Exhibit 20: Source: Technavio, 2015Orphan drug designations by therapy areas 2013
Exhibit 21: Average annual cost of orphan drugs per patient in US 2010-2014 ($)
Exhibit 22: Annual cost of several orphan drugs
Exhibit 23: Cost comparison of branded orphan drugs versus generic versions 2013 ($)
Exhibit 24: Orphan drug expenditure by therapeutic class 2007-2013
Exhibit 25: R&D cost for Phase III trial for orphan and non-orphan drugs 2013 and 2014 ($ billions)
Exhibit 26: The worldwide top late-stage and filed orphan drugs are given below:
Exhibit 27: Global orphan drugs market ($ billions)
Exhibit 28: Five forces analysis
Exhibit 29: Global orphan drugs market by product
Exhibit 30: Global orphan drugs market by product 2014
Exhibit 31: Global biologic orphan drugs market 2014-2019 ($ billions)
Exhibit 32: Global non-biologic orphan drugs market 2014-2019 ($ billions)
Exhibit 33: Global orphan drugs market by geographical segmentation 2014
Exhibit 34: Orphan drugs market in Americas 2014-2019 ($ billions)
Exhibit 35: Orphan drugs market in EMEA 2014-2019 ($ billions)
Exhibit 36: Orphan drugs market in APAC 2014-2019 ($ billions)
Exhibit 37: )Global orphan drugs market by geographical segmentation 2014-2019 ($ billions)
Exhibit 38: Drivers of global orphan drugs market
Exhibit 39: FDA filed to approved time: orphan versus non-orphan drugs (median time months)
Exhibit 40: Phase III trial length orphan versus non-orphan drugs (median length years)
Exhibit 41: Impact of drivers
Exhibit 42: Challenges in global orphan drugs market
Exhibit 43: Impact of key drivers and challenges
Exhibit 44: Trends in global orphan drugs market
Exhibit 45: BMS: Key takeaways
Exhibit 46: Celgene: Global year-over-year growth and revenue of Vidaza 2012-2014 ($ millions)
Exhibit 47: Celgene: Global year-over-year growth and revenue of Revlimid 2012-2014 ($ billions)
Exhibit 48: Celgene: Key takeaways
Exhibit 49: Novartis: Key takeaways
Exhibit 50: Pfizer: Year-on-year growth rate and revenue of Inlyta 2012-2014 ($ millions)
Exhibit 51: Pfizer: Key takeaways
Exhibit 52: Global year-over-year growth and revenue of Rituxan/MabThera 2010-2014 ($ billions)
Exhibit 53: Avastin: Global revenue and year-over-year growth 2010-2014 ($ billions)
Exhibit 54: Roche: Key takeaways
Exhibit 55: Worldwide orphan drug sales 2007-2013 ($ billions)
Exhibit 56: BMS: Business segmentation by revenue 2014
Exhibit 57: BMS: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 58: BMS: Geographical segmentation by revenue 2014
Exhibit 59: Celgene: Product segmentation by revenue 2014
Exhibit 60: Celgene: Product segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 61: Celgene: Geographical segmentation by revenue 2014
Exhibit 62: Roche: Business segmentation by revenue 2014
Exhibit 63: Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 64: Roche: Geographical segmentation by revenue 2014
Exhibit 65: Novartis: Business segmentation by revenue 2014
Exhibit 66: Novartis: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 67: Novartis: Geographical segmentation by revenue 2014
Exhibit 68: Pfizer: Business segmentation by revenue 2014
Exhibit 69: Pfizer: Business segmentation by revenue 2014 (%)
Exhibit 70: Pfizer: Geographical segmentation by revenue 2014
【レポート販売概要】
■ タイトル:希少疾病用医薬品(OD)の世界市場2015-2019■ 英文:Orphan Drugs Market 2015-2019
■ 発行日:2015年11月11日
■ 調査会社:Technavio
■ 商品コード:IRTNTR7493
■ 調査対象地域:グローバル
- 自動ラストマイルデリバリーの世界市場:用途別(ロジスティクス、ヘルスケア&医薬品、食品&飲料小売、その他)、ソリューション別(ハードウェア、ソフトウェア、サービス)、範囲別(短距離(20km))、車両タイプ別(空中配達ドローン、地上配達車両、自動運転トラック&バス)Autonomous last mile delivery consists of autonomous vehicles to deliver the product or service to customer’s doorstep without actually involving any human intervention in the entire process. It ensure that the product is delivered to the customer within a stipulated time period without hampering the dignity and market image of the company. Increased usage of internet along with the expansion in e …
- アメリカのエンジニアリング・サービス・アウトソーシング市場About Engineering Services Outsourcing Engineering service providers are aggressively working to enhance their capabilities through expanding their service offerings along with technology consulting services and IP-based solutions to sustain in the competition. The market is evolving with more mature outsourcing/delivery models and strategy formulation for nurturing sector-specific talent and M&A. …
- 世界のカンピロバクター検査市場The report presents a detailed analysis of the Campylobacter diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Campylobacter definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals &nbs …
- MnB rLP2086 (Meningococcal Vaccines):市場予測と分析(~2022)MnB rLP2086 (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. MnB rLP2086 is Pfizer’s …
- 航空機用アンテナの世界市場2018-2022118 Pages, November 2018 About this market The aviation industry is undergoing a technological revolution to improve flight efficiency and productivity in order to deliver a more enjoyable, comfortable, and safer experience for consumers. In-flight connectivity is one of the most important parts of flights that deliver an entertaining experience for passengers. In-flight entertainment systems have …
- エアボーンLiDARの世界市場予測(~2022年)“The airborne LiDAR market is projected to grow at a CAGR of 17.32% from 2017 to 2022” The airborne LiDAR market is projected to grow from an estimated USD 1,140.1 million in 2017 to reach USD 2,533.7 million by 2022, at a CAGR of 17.32% from 2017 to 2022. The airborne LiDAR market has been rapidly growing, especially in the Asia Pacific region, owing to the rapid infrastructural development and r …
- 北米の呼吸装置市場North America Respiratory Devices Market Outlook to 2021 Summary GlobalData’s new report, "North America Respiratory Devices Market Outlook to 2021", provides key market data on the North America Respiratory Devices market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Humidifiers, Oxygen Concentrators, Vent …
- 動物医療の世界市場:市場力学、動向、主要サプライヤ動向、技術動向などThis new 80-pages report from VPGMarketResearch.com analyzes marketing tactics and technological know-how of the world’s leading animal health companies, including: Five-year forecasts for: - Major market segments - Key geographic regions Assessment of major U.S. and international trends with potentially significant impact on the animal health industry during the next five years, i …
- 結晶系太陽電池モジュール市場動向:Outsourcing Module Production Proving to be a Strategic Move of Key Crystalline Module ManufacturersOutsourcing Module Production Proving to be a Strategic Move of Key Crystalline Module Manufacturers Summary The latest trend followed by the key crystalline solar module makers is outsourcing a certain percentage of their module production to their OEM (Original Equipment Manufacturers) partners. The driving force behind this trend has been the increase in PV demand more emphatically in the year …
- コンパニオン診断(CDx)の世界市場Companion Diagnostics (CDx) – your guide to developments, opportunities and revenues See what the future holds for companion diagnostics. Visiongain’s brand new report gives you revenue predictions for the CDx market and its submarkets from 2015, helping you stay ahead. Our 197-page report provides 114 tables, charts, and graphs. Discover the growing trends of this industry. In particular, our new …
- 世界における軍用機の整備・修理・オーバーホール(MRO)市場予測Competition in the MRO industry is increasing dramatically, as companies are hard pressed to make profits in a market ever more focused on performance and efficiencies. Aerospace technology is also getting so much more sophisticated, and MRO providers need to make increasingly larger investments in the equipment and skills required to service next-generation aerospace platforms and components. The …
- 世界のナノテクノロジーを用いたドラッグデリバリー市場動向(2012-2016)TechNavio's analysts forecast the Global Nanotechnology Drug Delivery market to grow at a CAGR of 73.97 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R&D cost. The Global Nanotechnology Drug Delivery market has also been witnessing an increase in customer support services. However, the increasing safety concerns could pose a challenge to th …
- 大人用おむつの世界市場:製品種類別(パンツタイプ、パッドタイプ、テープタイプ、その他)、流通経路別(オフライン&オンライン)The global adult diapers market was valued at $13.3 billion in 2018 and is projected to reach $24.1 billion by 2026, growing at a CAGR of 7.8% from 2019 to 2026. The global adult diapers market is segmented on the basis of product type, distribution channel, and region. By product type, the market is classified into pant type, pad type, tape, and others. By distribution channel, the market is divi …
- Peripheral Neuropathy (Sensory Neuropathy):グローバル臨床試験レビューH1, 2013Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2013" provides data on the Peripheral Neuropathy (Sensory Neuropathy) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Peripheral N …
- クラウド型イベント管理(Event Management as a Service)の世界市場2016-2020About Event Management The process of organizing a professional event for a particular audience is known as event management. Event management software has a set of features that helps organizers and organizations plan, execute, and monitor successful events. The report defines event management as a service as event management software that are delivered as software as a service (SaaS). The featur …